Latest News
Beximco Pharmaceuticals set to sell Mylan drugs in Bangladesh
Generics manufacturer Beximco Pharma would have exclusive rights to distribute Mylan’s portfolio of key monoclonal antibodies in Bangladesh
Beximco Pharmaceuticals Limited, which is co-founded by Salman F Rahman, recently signed an agreement with global healthcare group Mylan for the distribution of products throughout Bangladesh. Under the agreement, Beximco Pharma would get exclusive rights to launch Mylan’s portfolio of key monoclonal antibodies to treat different types of cancers and other medical conditions.
The first product, Dhaka-based Beximco Pharma would have exclusive rights to launch is Mylan’s breast cancer drug OgivriTM— a biosimilar based on Roche’s blockbuster drug Herceptin.
This deal is a follow-up of Beximco’s vision to provide patients with more affordable access to high quality, low-cost biosimilar products. As an emerging international generic drug player, Beximco has already facilitated pharmaceuticals export growth in Bangladesh. Due to its affordable generic medicine production capabilities, the company has been able to expand the export market to over 50 countries. Additionally, Salman F Rahman’s Beximco is also well accredited across multiple global regulatory authorities within the EU, Australia, China, and the Middle East.
That said, though local consumption of the generic medicine has already seen an increase, there were few issues such as limited brand marketing & less profit margin for the healthcare industry, impacting the prospective growth, thereby requiring world-class product development, marketing, and regulatory expertise. Thus, this commercial agreement between the two global manufacturers could foster the growth of biosimilar pharma products, especially in key therapeutic areas in the South Asian nation.
Nazmul Hassan, managing director of Beximco Pharmaceuticals, said, “We are incredibly excited to announce this commercial agreement with Mylan, the first of its kind in Bangladesh.”
Commenting on the launch, Rakesh Bamzai, President, Indian and Emerging Markets, Mylan said, through this commercial agreement with Beximco, our company is pleased to make Trastuzumab (monoclonal antibody to treat the body and breast cancer) accessible to patients in Bangladesh.
This alliance between the two pharmaceutical companies Mylan and Beximco is likely to market key monoclonal antibodies better in the South Asian nation. From here onwards, people in Bangladesh are expected to gain more affordable access to these much-needed products.
About the Author: Pierre Zarokian is the CEO of Submit Express, an SEO Company, and Reputation Stars, a Reputation Management company. Zarokian also writes for Search Engine Journal publication and has spoken at many industry trade shows.
